H.R. 2410 would authorize the Secretary of Health and Human Services, through the Centers for Disease Control and Prevention (CDC), to conduct surveillance and collect data on the prevalence of sickle cell disease (SCD). In addition, the bill would authorize the Secretary to develop public health initiatives that support community-based organizations in education activities and to support regional and state health departments in testing to identify SCD. H.R. 2410 would authorize the appropriation of about $4.5 million a year for fiscal years 2018 through 2022 to carry out those activities.
The bill would require CDC to build upon past activities related to SCD by conducting surveillance and developing public health initiatives through grants to States. Previous funding from the American Jobs Creation Act of 2004 of $10 million a year for SCD expired in 2009. There has been no explicit funding for SCD since 2009. However, CDC has continued to conduct activities related to SCD and other blood disorders. Based on historical spending for similar activities, CBO estimates that implementing H.R. 2410 would cost $18 million over the 2018-2022 period, primarily for additional staff and other administrative costs; the remaining amounts would be spent after 2022. Enacting H.R. 2410 would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply.
CBO estimates that enacting the legislation would not increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2028.
H.R. 2410 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act and would impose no costs on state, local, or tribal governments.